

**TDMS No.** 20523 - 02

**Test Type:** 90-DAY

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

**CAS Number:** TRIMVX

**Date Report Requested:** 03/24/2011

**Time Report Requested:** 15:32:43

**First Dose M/F:** 07/14/08 / 07/14/08

**Lab:** BNW

F1\_M3

**C Number:** C20523  
**Lock Date:** 02/24/2009  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.3.1  
**PWG Approval Date:** NONE

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF METAL WORKING FLUIDS (TRIM VX)**

**MALE MICE**

**Organ**

Larynx

Lung

Lung: Bronchiole

Nose

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

**FEMALE MICE**

**Organ**

Larynx

Lung

Lung: Bronchiole

Nose

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

**Morphology**

Hyperplasia

Inflammation Chronic

Metaplasia

Fibrosis

Infiltration Cellular Histiocyte

Inflammation Chronic

Hyperplasia

Inflammation

Accumulation, Hyaline Droplet

Accumulation, Hyaline Droplet

**Morphology**

Hyperplasia

Inflammation Chronic

Metaplasia

Fibrosis

Infiltration Cellular Histiocyte

Inflammation Chronic

Hyperplasia

Inflammation

Accumulation, Hyaline Droplet

Accumulation, Hyaline Droplet

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex</b>						
<b>Accessory Adrenal Cortical Nodule</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
<b>POLY-3 RATE (b)</b>	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
<b>POLY-3 PERCENT (g)</b>	10%	0%	0%	0%	0%	10%
<b>TERMINAL (d)</b>	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
<b>FIRST INCIDENCE</b>	95 (T)	---	---	---	---	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	(e)	(e)	(e)	(e)	(e)	P=0.760
<b>POLY 1.5</b>	(e)	(e)	(e)	(e)	(e)	P=0.760
<b>POLY 6</b>	(e)	(e)	(e)	(e)	(e)	P=0.760
<b>COCH-ARM / FISHERS</b>	P=0.650	(e)	(e)	(e)	(e)	P=0.763N
<b>MAX-ISO-POLY-3</b>	(e)	(e)	(e)	(e)	(e)	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex</b>						
<b>Vacuolization Cytoplasmic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
<b>POLY-3 RATE (b)</b>	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
<b>POLY-3 PERCENT (g)</b>	0%	0%	0%	0%	0%	0%
<b>TERMINAL (d)</b>	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
<b>FIRST INCIDENCE</b>	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	(n)	(n)	(n)	(n)	(n)	(n)
<b>POLY 1.5</b>	(n)	(n)	(n)	(n)	(n)	(n)
<b>POLY 6</b>	(n)	(n)	(n)	(n)	(n)	(n)
<b>COCH-ARM / FISHERS</b>	(n)	(n)	(n)	(n)	(n)	(n)
<b>MAX-ISO-POLY-3</b>	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex: Subcapsular Accessory Adrenal Cortical Nodule</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex: Subcapsular Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	10%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	95 (T)	---	---	---	---	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.381N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney Cyst</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
<b>POLY-3 RATE (b)</b>	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
<b>POLY-3 PERCENT (g)</b>	20%	0%	0%	0%	0%	10%
<b>TERMINAL (d)</b>	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
<b>FIRST INCIDENCE</b>	95 (T)	---	---	---	---	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	(e)	(e)	(e)	(e)	(e)	P=0.500N
<b>POLY 1.5</b>	(e)	(e)	(e)	(e)	(e)	P=0.500N
<b>POLY 6</b>	(e)	(e)	(e)	(e)	(e)	P=0.500N
<b>COCH-ARM / FISHERS</b>	P=0.381N	(e)	(e)	(e)	(e)	P=0.500N
<b>MAX-ISO-POLY-3</b>	(e)	(e)	(e)	(e)	(e)	P=0.274N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney</b>						
<b>Nephropathy</b>						
<b>LESION RATES</b>						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	95 (T)	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	8/10 (80%)	9/10 (90%)
POLY-3 RATE (b)	0/10.00	0/10.00	2/10.00	9/10.00	8/10.00	9/10.00
POLY-3 PERCENT (g)	0%	0%	20%	90%	80%	90%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	8/10 (80%)	9/10 (90%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.237	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.066	P<0.001**	P<0.001**	P<0.001**

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	4/10 (40%)	0/10 (0%)	3/10 (30%)	1/10 (10%)	0/10 (0%)
<b>POLY-3 RATE (b)</b>	0/10.00	4/10.00	0/10.00	3/10.00	1/10.00	0/10.00
<b>POLY-3 PERCENT (g)</b>	0%	40%	0%	30%	10%	0%
<b>TERMINAL (d)</b>	0/10 (0%)	4/10 (40%)	0/10 (0%)	3/10 (30%)	1/10 (10%)	0/10 (0%)
<b>FIRST INCIDENCE</b>	---	95 (T)	---	95 (T)	95 (T)	---
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
<b>POLY 1.5</b>	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
<b>POLY 6</b>	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
<b>COCH-ARM / FISHERS</b>	P=0.178N	P=0.043*	(e)	P=0.105	P=0.500	(e)
<b>MAX-ISO-POLY-3</b>	P=0.078N	P=0.007**	(e)	P=0.025*	P=0.158	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx</b>						
<b>Metaplasia</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	100%	100%	100%	100%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung Fibrosis</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	8/10 (80%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	8/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	80%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	8/10 (80%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	P<0.001**	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung</b>						
<b>Infiltration Cellular Histiocyte</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	0/10.00	2/10.00	9/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	0%	20%	90%	100%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	---	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P<0.001**	(e)	P=0.237	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	P=0.066	P<0.001**	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	0/10.00	4/10.00	10/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	0%	40%	100%	100%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	---	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P<0.001**	(e)	P=0.043*	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	P=0.007**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung: Bronchiole Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	90%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose Inflammation</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	7/10 (70%)	8/10 (80%)	8/10 (80%)	8/10 (80%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	7/10.00	8/10.00	8/10.00	8/10.00	10/10.00
POLY-3 PERCENT (g)	0%	70%	80%	80%	80%	100%
TERMINAL (d)	0/10 (0%)	7/10 (70%)	8/10 (80%)	8/10 (80%)	8/10 (80%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Olfactory Epithelium Accumulation, Hyaline Droplet</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	100%	100%	100%	100%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Respiratory Epithelium Accumulation, Hyaline Droplet</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Respiratory Epithelium Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Testes: Germinal Epithelium Degeneration</b>						
<b>LESION RATES</b>						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	95 (T)	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex</b>						
<b>Accessory Adrenal Cortical Nodule</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/1.00	0/1.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex</b>						
<b>Vacuolization Cytoplasmic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	6/10 (60%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
<b>POLY-3 RATE (b)</b>	6/10.00	0/0.00	0/1.00	0/1.00	0/0.00	4/10.00
<b>POLY-3 PERCENT (g)</b>	60%	0%	0%	0%	0%	40%
<b>TERMINAL (d)</b>	6/10 (60%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
<b>FIRST INCIDENCE</b>	96 (T)	---	---	---	---	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
<b>POLY 1.5</b>	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
<b>POLY 6</b>	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
<b>COCH-ARM / FISHERS</b>	P=0.345N	(e)	P=0.455N	P=0.455N	(e)	P=0.328N
<b>MAX-ISO-POLY-3</b>	(e)	(e)	P=0.205N	P=0.205N	(e)	P=0.193N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex: Subcapsular Accessory Adrenal Cortical Nodule</b>						
<b>LESION RATES</b>						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/1.00	0/1.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
POLY 1.5	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
POLY 6	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
COCH-ARM / FISHERS	P=0.620	(e)	P=0.909N	P=0.909N	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	P=0.409N	P=0.409N	(e)	P=1.000

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Adrenal Cortex: Subcapsular Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	5/10 (50%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	5/10 (50%)
POLY-3 RATE (b)	5/10.00	0/0.00	0/1.00	0/1.00	0/0.00	5/10.00
POLY-3 PERCENT (g)	50%	0%	0%	0%	0%	50%
TERMINAL (d)	5/10 (50%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	5/10 (50%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
POLY 1.5	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
POLY 6	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
COCH-ARM / FISHERS	P=0.489	(e)	P=0.545N	P=0.545N	(e)	P=0.672N
MAX-ISO-POLY-3	(e)	(e)	P=0.251N	P=0.251N	(e)	P=1.000

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney Cyst</b>						
<b>LESION RATES</b>						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	96 (T)	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
<b>STATISTICAL TESTS</b>						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Kidney Nephropathy</b>						
<b>LESION RATES</b>						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.760
COCH-ARM / FISHERS	P=0.650	(e)	(e)	(e)	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx Hyperplasia</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
<b>POLY-3 RATE (b)</b>	0/10.00	0/10.00	1/10.00	7/10.00	7/10.00	8/10.00
<b>POLY-3 PERCENT (g)</b>	0%	0%	10%	70%	70%	80%
<b>TERMINAL (d)</b>	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
<b>FIRST INCIDENCE</b>	---	---	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P<0.001**	(e)	P=0.500	P=0.002**	P=0.002**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	P=0.158	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	4/10 (40%)	5/10 (50%)	8/10 (80%)	9/10 (90%)	5/10 (50%)
<b>POLY-3 RATE (b)</b>	0/10.00	4/10.00	5/10.00	8/10.00	9/10.00	5/10.00
<b>POLY-3 PERCENT (g)</b>	0%	40%	50%	80%	90%	50%
<b>TERMINAL (d)</b>	0/10 (0%)	4/10 (40%)	5/10 (50%)	8/10 (80%)	9/10 (90%)	5/10 (50%)
<b>FIRST INCIDENCE</b>	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
<b>POLY 1.5</b>	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
<b>POLY 6</b>	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
<b>COCH-ARM / FISHERS</b>	P=0.063	P=0.043*	P=0.016*	P<0.001**	P<0.001**	P=0.016*
<b>MAX-ISO-POLY-3</b>	P<0.001**	P=0.007**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Larynx Metaplasia</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	100%	100%	100%	100%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung Fibrosis</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung</b>						
<b>Infiltration Cellular Histiocyte</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	0/10.00	0/10.00	1/10.00	5/10.00	9/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	0%	0%	10%	50%	90%	100%
<b>TERMINAL (d)</b>	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	---	---	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
<b>POLY 6</b>	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P<0.001**	(e)	P=0.500	P=0.016*	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	(e)	P=0.158	P<0.001**	P<0.001**	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung</b>						
<b>Inflammation Chronic</b>						
<b>LESION RATES</b>						
<b>OVERALL (a)</b>	1/10 (10%)	0/10 (0%)	2/10 (20%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>POLY-3 RATE (b)</b>	1/10.00	0/10.00	2/10.00	10/10.00	10/10.00	10/10.00
<b>POLY-3 PERCENT (g)</b>	10%	0%	20%	100%	100%	100%
<b>TERMINAL (d)</b>	1/10 (10%)	0/10 (0%)	2/10 (20%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
<b>FIRST INCIDENCE</b>	96 (T)	---	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
<b>POLY 3</b>	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>POLY 1.5</b>	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>POLY 6</b>	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>COCH-ARM / FISHERS</b>	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
<b>MAX-ISO-POLY-3</b>	P<0.001**	P=0.158N	P=0.274	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Lung: Bronchiole Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	4/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	40%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.043*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.007**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose Inflammation</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	1/10 (10%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	7/10 (70%)
POLY-3 RATE (b)	0/10.00	1/10.00	6/10.00	5/10.00	10/10.00	7/10.00
POLY-3 PERCENT (g)	0%	10%	60%	50%	100%	70%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	7/10 (70%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P=0.005**	P=0.016*	P<0.001**	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.158	P<0.001**	P<0.001**	(e)	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Olfactory Epithelium Accumulation, Hyaline Droplet</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Respiratory Epithelium Accumulation, Hyaline Droplet</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
<b>STATISTICAL TESTS</b>						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
<b>Nose: Respiratory Epithelium Hyperplasia</b>						
<b>LESION RATES</b>						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	96 (T)	---
<b>STATISTICAL TESTS</b>						
POLY 3	P=0.605	(e)	(e)	(e)	P=0.500	(e)
POLY 1.5	P=0.605	(e)	(e)	(e)	P=0.500	(e)
POLY 6	P=0.605	(e)	(e)	(e)	P=0.500	(e)
COCH-ARM / FISHERS	P=0.605	(e)	(e)	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.193	(e)	(e)	(e)	P=0.158	(e)

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (e) Value of statistic cannot be computed.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (n) No statistics are calculated if all dose groups have fewer than two tumors.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*